- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07696429
Effect of Topical Anesthesia on the Phonation Process During High-Speed Digital Imaging Laryngoscopy in Patients With Laryngopharyngeal Reflux
The Effect of Topical Anesthesia on the Phonation Process During High-Speed Digital Imaging Laryngoscopy in Patients With Laryngopharyngeal Reflux: A Randomized Double-Blind Placebo-Controlled Crossover Study
The goal of this clinical trial is to learn if topical anesthesia (lidocaine spray) affects the phonation process during High-Speed Digital Imaging (HSDI) laryngoscopy in adults with laryngopharyngeal reflux (LPR). The main questions it aims to answer are:
Does topical anesthesia change phonation process parameters (such as mucosal wave amplitude, glottal closure pattern, phase symmetry, and periodicity) as assessed on the Voice-Vibratory Assessment with Laryngeal Imaging (VALI) form? Does topical anesthesia change the type of glottal insufficiency observed during phonation?
Researchers will compare HSDI recordings performed with topical anesthesia (lidocaine spray) to recordings performed with placebo (physiological saline) to see if topical anesthesia alters phonation process findings.
Participants will:
Undergo HSDI laryngoscopy recording on two consecutive days, once with topical anesthesia and once with placebo, in a randomized, double-blind order Have a detailed medical history taken and complete the Reflux Symptom Index (RSI) questionnaire Undergo fiberendoscopic examination for determination of the Reflux Finding Score (RFS) Return for a follow-up examination within three months, during which they will continue proton pump inhibitor therapy and hygienic-dietary measures
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Standard clinical practice for rigid transoral laryngoscopy, including High-Speed Digital Imaging (HSDI), includes the elective use of topical anesthesia of the oral cavity and oropharynx; however, clearly defined recommendations and indications for its use are lacking, and its potential effect on the phonation process has not been unequivocally established. Upon application to the oral cavity and oropharynx, anesthetic may drain into the larynx and desensitize the mucosa, potentially affecting sensorimotor aspects of laryngeal function. Existing studies on the effect of topical anesthesia on phonation during laryngoscopy are limited and report contradictory findings.
This prospective, randomized, double-blind, placebo-controlled crossover study assigned each participant a unique number via random number generator, determining the order of recording modalities (even numbers recorded first with topical anesthesia, odd numbers first without). Once assigned, the order could not be changed. Randomization and testing order were concealed from the examiner performing the HSDI recording.
Topical anesthesia (lidocaine spray, 100 mg/ml, 0.1 ml per actuation) or physiological saline (placebo) was applied by a junior physician, blinded to the substance used, to the base of the tongue, posterior pharyngeal wall, and soft palate (one actuation per site). HSDI recording was performed 5 minutes after application. Each participant underwent recording in both modalities on two consecutive days, a period considered sufficiently short to avoid confounding phonotraumatic, hormonal, or health-related changes.
HSDI recordings were performed by an experienced otorhinolaryngologist and phoniatrician (>5 years of experience) using a rigid 90° endoscope (Wolf 5562 HRES ENDOCAM with Wolf Auto LP 5132 Hlight light source, Richard Wolf GmbH, Knittlingen, Germany). Participants were seated upright with the tongue held protruded; the endoscope was passed along the midline of the tongue to visualize the full length of the vocal folds. Participants phonated the vowel /a/ dynamically and frequentially, and a 2-second HSDI recording was captured. Recordings were reviewed for quality (minimum 1,000 clear, focused, consecutive images of the full vocal fold length during the steady phonation phase); inadequate recordings were repeated. Fundamental frequency and phonation intensity were recorded via a microphone mounted on the endoscope with software processing. Maximum Phonation Time was determined from three stopwatch-timed measurements of sustained /a/ phonation, taken immediately before and after HSDI recording.
Each HSDI recording was independently assessed by two experienced otorhinolaryngologists/phoniatricians (>5 years of experience) using visual-perceptual analysis. Discrepancies in parameter scoring were resolved through joint re-analysis and discussion until consensus was reached before proceeding to the next recording. Assessment was standardized using the Voice-Vibratory Assessment with Laryngeal Imaging (VALI) form and the European Laryngological Society (ELS) form for glottal closure pattern classification, along with a modified classification of glottal insufficiency. The Reflux Finding Score was re-determined from recordings according to the Belafsky et al. classification.
Participants underwent a follow-up examination within three months of study participation, during which the Reflux Finding Score (via fiberendoscopy) and Reflux Symptom Index (via questionnaire) were re-assessed while participants continued regular proton pump inhibitor therapy and hygienic-dietary measures; participants with persistent pathological findings were excluded from final analysis.
Statistical analysis included the Kolmogorov-Smirnov test for normality of distribution. Normally distributed variables were described using means and standard deviations; non-normally distributed variables were described using medians and ranges. Differences between recordings with and without topical anesthesia were tested using the paired t-test (parametric) or Wilcoxon signed-rank test (non-parametric), as appropriate. Spearman correlation and regression analysis were used to explore associations between anatomical structures and measured characteristics. A p-value <0.05 was considered statistically significant.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Zagreb, Chorwacja, 10000
- University Hospital Centre Zagreb (KBC Zagreb), Department of ORL Head and Neck Surgery
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Newly diagnosed laryngopharyngeal reflux (LPR), defined as Reflux Symptom Index (RSI) >13 and Reflux Finding Score (RFS) >7 Age 18-45 years No prior HSDI recording Ability to tolerate HSDI examination without topical anesthesia
Exclusion Criteria:
- Known allergy to lidocaine and/or other allergens Acute respiratory infection within the preceding month Current smokers or regular alcohol consumers Chronic rhinosinusitis Prior surgery and/or radiotherapy of the larynx, neck, or thyroid gland Inability to visualize the full length of the vocal folds during the 2-second HSDI recording for anatomical reasons
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Anesthesia-First Sequence (A→B)
Participants received topical anesthesia (lidocaine spray, 100 mg/ml) applied to the base of the tongue, posterior pharyngeal wall, and soft palate on Day 1, followed by HSDI laryngoscopy 5 minutes later.
On Day 2, the same participants received placebo (physiological saline), identically applied, followed by HSDI laryngoscopy.
Order was determined by randomization.
|
Lidocaine spray, 100 mg/ml, administered topically as one actuation (0.1 ml) each to the base of the tongue, posterior pharyngeal wall, and soft palate, approximately 5 minutes prior to HSDI laryngoscopy.
Administered once per participant, on one of the two study days according to randomized sequence assignment.
Inne nazwy:
Physiological saline (0.9% NaCl) spray, administered topically as one actuation (0.1 ml) each to the base of the tongue, posterior pharyngeal wall, and soft palate, approximately 5 minutes prior to HSDI laryngoscopy.
Administered once per participant, on one of the two study days according to randomized sequence assignment, identical in application technique to the lidocaine intervention.
Inne nazwy:
|
|
Komparator placebo: Placebo-First Sequence (B→A)
Participants received placebo (physiological saline) applied to the base of the tongue, posterior pharyngeal wall, and soft palate on Day 1, followed by HSDI laryngoscopy 5 minutes later.
On Day 2, the same participants received topical anesthesia (lidocaine spray, 100 mg/ml), identically applied, followed by HSDI laryngoscopy.
Order was determined by randomization.
|
Lidocaine spray, 100 mg/ml, administered topically as one actuation (0.1 ml) each to the base of the tongue, posterior pharyngeal wall, and soft palate, approximately 5 minutes prior to HSDI laryngoscopy.
Administered once per participant, on one of the two study days according to randomized sequence assignment.
Inne nazwy:
Physiological saline (0.9% NaCl) spray, administered topically as one actuation (0.1 ml) each to the base of the tongue, posterior pharyngeal wall, and soft palate, approximately 5 minutes prior to HSDI laryngoscopy.
Administered once per participant, on one of the two study days according to randomized sequence assignment, identical in application technique to the lidocaine intervention.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Phonation Process Parameters Assessed by the Voice-Vibratory Assessment with Laryngeal Imaging (VALI) Form
Ramy czasowe: Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
Parameters assessed by visual-perceptual analysis of HSDI recordings using the VALI form: glottal sufficiency pattern, mucosal wave amplitude, free edge amplitude, vertical level of the vocal folds, non-vibrating segment of the vocal fold, supraglottic structure activation, free edge contour, open-to-closed phase ratio of the glottal cycle, phase symmetry of the vocal folds, periodicity, and axis shift of the vocal folds.
Each recording was independently scored by two blinded raters, with discrepancies resolved by consensus.
|
Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
|
Change in Glottal Closure Pattern (European Laryngological Society Classification)
Ramy czasowe: Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
Glottal closure pattern during the initial phase of the glottal cycle, classified according to the European Laryngological Society (ELS) form (e.g., concave, convex, straight, complex), assessed by visual-perceptual analysis of HSDI recordings.
|
Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
|
Change in Type of Glottal Insufficiency (European Laryngological Society Classification)
Ramy czasowe: Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
Type of glottal insufficiency during phonation, classified according to a modified European Laryngological Society (ELS) classification (e.g., complete glottal closure, incomplete closure in the cartilaginous part of the glottis), assessed by visual-perceptual analysis of HSDI recordings.
|
Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
|
Change in Acoustic Voice Parameters (Fundamental Frequency and Phonation Intensity)
Ramy czasowe: Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
Fundamental frequency (F0, Hz) and phonation intensity (dB) during phonation of the sustained vowel /a/, recorded via a microphone mounted on the endoscope with software processing.
|
Assessed once per recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
|
Change in Maximum Phonation Time (MPT)
Ramy czasowe: Assessed immediately before and after each HSDI recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
Maximum duration (seconds) of sustained, dynamically stationary phonation of the vowel /a/ following maximal inhalation, determined as the longest of three stopwatch-timed trials performed immediately before and after HSDI recording.
|
Assessed immediately before and after each HSDI recording session; each participant recorded on 2 consecutive days (with and without topical anesthesia)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Mario Bilić, prof. dr. sc. dr. med., Department of ORL Head and Neck Surgery, University Hospital Centre Zagreb, Croatia
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Oddechowego
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby przełyku
- Choroby krtani
- Zaburzenia motoryki przełyku
- Zaburzenia połykania
- Refluks żołądkowo-przełykowy
- Refluks krtaniowo-gardłowy
- Organiczne chemikalia
- Anilidy
- Amides
- Związki aniliny
- Aminy
- Acetanilidy
- Lidokaina
Inne numery identyfikacyjne badania
- Class No.8.1-19/31-2
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Refluks krtaniowo-gardłowy
-
University Hospital Birmingham NHS Foundation TrustUniversity of Birmingham; Dystrophic Epidermolysis Bullosa Research Association...Rejestracja na zaproszeniePęcherzowe oddzielanie się naskórka | Zespół skórny Laryngo OnychoZjednoczone Królestwo
Badania kliniczne na Lidocaine 10% Spray
-
Imperial College LondonGlaxoSmithKlineZakończony
-
YuvellCroma-Pharma GmbHRekrutacyjnyKurze łapki | Zwiększenie objętości ust | Starzenie się ust | Zmarszczki wokół ustAustria
-
West China HospitalWycofane
-
VistaGen Therapeutics, Inc.RekrutacyjnyFobia społecznaStany Zjednoczone
-
Primus PharmaceuticalsProsoft ClinicalZakończonyŁuszczycaStany Zjednoczone
-
Therapeutics, Inc.ZakończonyŁuszczyca plackowataStany Zjednoczone
-
University of ChicagoZakończony
-
Therapeutics, Inc.ZakończonyŁuszczyca plackowataStany Zjednoczone
-
Schwabe Pharma ItaliaZakończonyZapalenie gardła | Ból gardłaWłochy
-
Primus PharmaceuticalsProsoft ClinicalZakończony